Comparative Pharmacology
Head-to-head clinical analysis: BYDUREON BCISE versus BYDUREON PEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BYDUREON BCISE versus BYDUREON PEN.
BYDUREON BCISE vs BYDUREON PEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BYDUREON BCISE (exenatide extended-release) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It activates the GLP-1 receptor, increasing glucose-dependent insulin secretion, decreasing glucagon secretion, slowing gastric emptying, and promoting satiety.
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety.
Subcutaneous injection, 2 mg once weekly.
2 mg subcutaneously once every 7 days (weekly)
None Documented
None Documented
Terminal elimination half-life is approximately 2.4 hours after subcutaneous administration, but the extended-release formulation provides prolonged exposure over 2 weeks via continuous release from microspheres.
Terminal elimination half-life is 2.4 hours following subcutaneous administration; due to extended-release microspheres, systemic exposure is sustained over 10 weeks with multiple dosing (effective half-life ~2 weeks).
Excreted primarily via renal degradation; no significant biliary or fecal excretion. Approximately 70% of the dose is eliminated as intact exenatide via glomerular filtration and proteolytic catabolism.
Renal excretion of intact exenatide via glomerular filtration and proteolytic degradation; approximately 100% of administered dose eliminated via renal pathways (urine) as intact peptide and metabolites.
Category C
Category C
Antidiabetic
Antidiabetic